5th Annual Kinase Inhibitor Chemistry

The human kinome has proven to be a large class of chemically tractable drug targets, with a significant portion of drug development efforts geared toward the discovery and optimization of chemical matter modulating kinase activity. Yet, despite the hundreds of kinase inhibitors currently in discovery, preclinical and clinical phases, a relatively small subset of the kinome has been thoroughly explored with selective small molecule inhibitors.

Thus, in this highly competitive space, continued success requires the identification of novel kinase targets, obtaining target selectivity and specificity, developing compounds with non-traditional mechanisms of inhibition - such as binding outside the ATP site or cyclic inhibitors - and applying kinase inhibitors to non-oncology indications. Cambridge Healthtech Institute’s fifth annual Kinase Inhibitor Chemistry will once again join academic and industry leaders to network, collaborate and discuss practical solutions to these challenges, while exploring the ever expanding arena of kinase drug discovery.